PMID- 30560509
OWN - NLM
STAT- MEDLINE
DCOM- 20190426
LR  - 20200225
IS  - 1749-0774 (Electronic)
IS  - 0914-7470 (Linking)
VI  - 32
IP  - 2
DP  - 2019 Apr
TI  - KLP-PI: a new prognostic index for luminal B HER-2-negative breast cancer.
PG  - 172-184
LID - 10.1007/s13577-018-00229-x [doi]
AB  - Luminal B HER-2-negative (LBHN) subtype is one of the major subtypes of breast 
      cancer according to different features, clinical behaviors, and treatment 
      response. The LBHN subtype shows a poor prognosis and is insensitive to endocrine 
      therapy. Our work aim is to investigate the prognostic factor in the LBHN 
      subgroup and, meanwhile, try to obtain an optimal prognostic index (PI) 
      contrapose LBHN subgroup which helps to guide chemotherapy. A total of 515 female 
      LBNH patients who underwent diagnosis and surgery at our hospitals from August 
      2008 to August 2018 were enrolled. Clinical-pathological information was obtained 
      and immunohistochemistry result was available. From these cases, a 30% Ki-67 LI 
      was employed to divide LBHN into two groups with low and high levels; high Ki-67 
      LI was associated with GIII tumor grade (P < 0.001), positive axillary lymph 
      nodes (ALN) status (P = 0.018) and negative PR status (P = 0.016), and also 
      seemed to be related to T2-T3 tumor size (P = 0.058). High Ki-67 level 
      (HR = 3.30; P < 0.011), positive ALN (HR = 7.29; P < 0.001) and PR negative 
      (HR = 2.63; P = 0.034) significantly associated with poor 5-year DFS in 
      multivariate Cox's proportional hazard regression model. A novel prognosis 
      prediction model (KLP-PI), based on Ki-67 LI, ALN and PR status, showed a better 
      discriminatory ability compared with traditional Nottingham prognostic index 
      targeted to LBHN breast cancer. Our study highlights that high Ki-67 LI, positive 
      ALN and negative PR status were associated with poor outcome in LBHN patients, 
      and composed by these prognostic factors, KLP-PI improves the prognostic 
      assessment using the Nottingham Prognostic Index when aiming at LBHN subtype.
FAU - Pan, Chuanmeng
AU  - Pan C
AD  - Department of General Surgery, The Second Affiliated Hospital and Yuying 
      Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, 
      People's Republic of China.
FAU - Bhandari, Adheesh
AU  - Bhandari A
AD  - Department of Thyroid and Breast Surgery, The First Affiliated Hospital of 
      Wenzhou Medical University, Nanbai Xiang Street, Wenzhou, 325000, Zhejiang, 
      People's Republic of China.
FAU - Liu, Yehuan
AU  - Liu Y
AD  - Department of Thyroid and Breast Surgery, The First Affiliated Hospital of 
      Wenzhou Medical University, Nanbai Xiang Street, Wenzhou, 325000, Zhejiang, 
      People's Republic of China.
FAU - Xia, Erjie
AU  - Xia E
AD  - Department of Thyroid and Breast Surgery, The First Affiliated Hospital of 
      Wenzhou Medical University, Nanbai Xiang Street, Wenzhou, 325000, Zhejiang, 
      People's Republic of China.
FAU - Lin, Lizhi
AU  - Lin L
AD  - Department of Thyroid and Breast Surgery, The First Affiliated Hospital of 
      Wenzhou Medical University, Nanbai Xiang Street, Wenzhou, 325000, Zhejiang, 
      People's Republic of China.
FAU - Lv, Shixu
AU  - Lv S
AD  - Department of Thyroid and Breast Surgery, The First Affiliated Hospital of 
      Wenzhou Medical University, Nanbai Xiang Street, Wenzhou, 325000, Zhejiang, 
      People's Republic of China. lvshixu@outlook.com.
FAU - Wang, Ouchen
AU  - Wang O
AUID- ORCID: 0000-0001-5230-379X
AD  - Department of Thyroid and Breast Surgery, The First Affiliated Hospital of 
      Wenzhou Medical University, Nanbai Xiang Street, Wenzhou, 325000, Zhejiang, 
      People's Republic of China. woc863@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20181217
PL  - Japan
TA  - Hum Cell
JT  - Human cell
JID - 8912329
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Ki-67 Antigen)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Axilla
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/classification/*diagnosis/genetics/*pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - *Kaplan-Meier Estimate
MH  - Ki-67 Antigen/analysis
MH  - Lymph Nodes
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Receptor, ErbB-2/*analysis
MH  - Severity of Illness Index
OTO - NOTNLM
OT  - Axillary lymph nodes
OT  - Breast cancer
OT  - Ki-67
OT  - Luminal B HER-2 negative
OT  - PR status
OT  - Prognostic index
EDAT- 2018/12/19 06:00
MHDA- 2019/04/27 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/10/07 00:00 [received]
PHST- 2018/12/02 00:00 [accepted]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2019/04/27 06:00 [medline]
PHST- 2018/12/19 06:00 [entrez]
AID - 10.1007/s13577-018-00229-x [pii]
AID - 10.1007/s13577-018-00229-x [doi]
PST - ppublish
SO  - Hum Cell. 2019 Apr;32(2):172-184. doi: 10.1007/s13577-018-00229-x. Epub 2018 Dec 
      17.